BGLAP and Myalgia: Secondary outcomes included changes in BMD [17] of the proximal femur, bone turnover markers (procollagen type I N-terminal propeptide (PINP), β-C-terminal telopeptide (β-CTX), and N-terminal mid-fragment of osteocalcin (N-MID osteocalcin)) [18], and the incidence of adverse events such as cement leakage, myalgia, arthralgia, pyrexia, and influenza-like symptoms.